loaded solid lipid nanoparticles (Ber-SLN) composed of cremophor EL and glyceryl behenate were prepared by high pressure homogenization technique. Anti-diabetic effects of Ber-SLN relative to efficacy of bulk Ber were evaluated in streptozotocin (STZ) induced diabetic C57BL/6 mice. The particle size and zeta potential of Ber-SLN were 154.3 ± 4.1 nm and −19.7 ± 0.46 mV, respectively. Ber-SLN (50 mg/kg) treatment via oral gavage 8 weeks resulted in a superior hypoglycemic and total cholesterol (TC) and body weight reduction effects compared to an equivalent dose of bulk Ber and metformin (Met, 300 mg/kg). These data indicate that a low dosage Ber-SLN decreases blood glucose and improves lipid metabolism in type 2 diabetic C57BL/6 mice. These results suggest that the delivery of Ber as SLN is a promising approach for treating type 2 diabetes.